Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

Summary

This study will evaluate the safety and efficacy of intraperitoneal administration of Bevacizumab to prevent the recurrence of malignant ascites. Ten patients will receive intraperitoneal Bevacizumab 200 mg in 250 ml of normal saline for infusion every two weeks for up to six weeks, or a maximum of three treatments.

Timeline

Start

2015-06

Primary completion

2015-08

Completion

2015-08

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of Enrollment”

Drugs

Indications